Astellas, Others Map Plans To Use iPS Cells For Testing Drug Effects
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma plans to establish a regenerative-medicine unit in April, one of the latest moves by drug makers to take advantage of induced pluripotent stem cells.